Great Point Partners LLC Pliant Therapeutics, Inc. Transaction History

Great Point Partners LLC

$216 Million
Q3 2024

A detailed history of Great Point Partners LLC transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Great Point Partners LLC holds 1,910,121 shares of PLRX stock, worth $23.5 Million. This represents 9.9% of its overall portfolio holdings.

Number of Shares

1,910,121

Previous 2,636,864 27.56%

Holding current value

$23.5 Million

Previous $28.3 Million 24.46%

% of portfolio

9.9%

Previous 7.51%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$10.52 - $14.35 $7.65 Million - $10.4 Million	-726,743 Reduced 27.56%	1,910,121 $21.4 Million
Q2 2024 Aug 14, 2024	BUY	$10.58 - $15.61 $8.31 Million - $12.3 Million	785,000 Added 42.39%	2,636,864 $28.3 Million
Q1 2024 May 15, 2024	BUY	$14.14 - $19.59 $405,535 - $561,841	28,680 Added 1.57%	1,851,864 $27.6 Million
Q4 2023 Feb 14, 2024	BUY	$12.85 - $19.15 $873,800 - $1.3 Million	68,000 Added 3.87%	1,823,184 $33 Million
Q3 2023 Nov 14, 2023	BUY	$14.58 - $20.15 $2.99 Million - $4.13 Million	205,000 Added 13.22%	1,755,184 $30.4 Million
Q2 2023 Aug 14, 2023	BUY	$18.12 - $30.56 $6.13 Million - $10.3 Million	338,088 Added 27.89%	1,550,184 $28.1 Million
Q1 2023 May 15, 2023	SELL	$18.73 - $36.26 $2.07 Million - $4.02 Million	-110,774 Reduced 8.37%	1,212,096 $32.2 Million
Q4 2022 Feb 14, 2023	BUY	$17.0 - $25.43 $4.78 Million - $7.15 Million	281,133 Added 26.99%	1,322,870 $25.6 Million
Q3 2022 Nov 14, 2022	BUY	$7.67 - $24.23 $5.25 Million - $16.6 Million	684,474 Added 191.59%	1,041,737 $21.8 Million
Q2 2022 Aug 15, 2022	BUY	$4.11 - $8.75 $1.47 Million - $3.13 Million	357,263 New	357,263 $2.86 Million

Others Institutions Holding PLRX

# of Institutions

168

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.

Account

Great Point Partners LLC Pliant Therapeutics, Inc. Transaction History